Narazaciclib is a new generation, highly selective, small-molecule CDK4/6 inhibitor that has shown remarkable potential in the treatment of advanced-stage cancers. It is one of the recently introduced drugs in the cancer treatment industry and has garnered significant attention in the medical community.
With the increasing interest in Narazaciclib, there has been a growing need to understand the product's nuances, health benefits, potential effects, side effects, dosing, and safety profile. In this article, we will explore all aspects of Narazaciclib, starting from its introduction to its possible conclusion.
Introduction: Chemical name: (R)-3-(1H-pyrazol-1-yl)-1-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)amino)phenyl)urea Molecular Formula: C22H19N9O Formula weight: 433.45 g/mol CAS No: 1357470-29-1
Top ten search keywords & synonyms:
Synonyms:
Health benefits of this product: Narazaciclib has been reportedly used as a CDK4/6 inhibitor for treating patients with advanced-stage cancer. This drug works by blocking the activation of proteins, CDK4/6, which are critical in the cell division process. CDK4/6 factors play a fundamental role in various forms of cancer. By inhibiting CDK4/6, Narazaciclib has the potential to stop or slow down the growth of cancer cells.
Narazaciclib has demonstrated impressive results in pre-clinical trials for the treatment of diverse types of cancer, including breast, lung, and pancreatic cancer. It has exhibited a good response with a marked improvement in progression-free survival (PFS) in patients. Narazaciclib aims to improve the overall survival of patients, maximize cancer remission, and improve quality of life.
Product mechanism: As mentioned earlier, Narazaciclib operates as a potent CDK4/6 inhibitor, halting the growth of cancer cells and reducing their proliferation rate. CDK (Cyclin-dependent kinases) are fundamental factors responsible for regulating the cell cycle and differentiation process. This class of proteins can stimulate tumor cell proliferation and contribute to disease progression. By inhibiting CDK4/6 activity, Narazaciclib helps stop or slow down cancerous tumor growth by halting cell growth and division.
Safety: Clinical studies suggest that Narazaciclib's safety profile is good, with no severe or unexpected adverse effects observed. The drug has undergone extensive preclinical testing, and its safety profile has been demonstrated in several phase 1 and phase 2 trials. Typically, side effects experienced were generally mild to moderate and included fatigue, nausea, constipation, and diarrhea. Physicians, however, must monitor patients regularly and report any unusual effect that may occur.
Side effects: Some common side effects of Narazaciclib include:
It is essential to note that these side effects may not occur in every individual. Patients must receive adequate counseling and medical care, and promptly report any unexpected or severe effects.
Dosing information: Based on recent clinical data, Narazaciclib is administered orally at a dose of 300mg once daily on a 21 days on/7 days off schedule. However, dosing may vary depending on the type of cancer being treated. Physicians will assess the patient's medical condition and prescribe the most appropriate dose.
Conclusion: Narazaciclib CAS: 1357470-29-1 is an innovative CDK4/6 inhibitor designed to treat patients with advanced-stage cancer. It holds great promise in the treatment of various types of cancer, including breast, lung, and pancreatic. While clinical trials continue, health professionals, cancer patients, and their caregivers should be well informed of the product's health benefits, potential effects, dosing requirements, and potential side effects of Narazaciclib。
